Get started
Author

Haixiang Cao

Observed names: H. Cao, Hai-Xiang Cao, Hai‐Xiang Cao
ORCID: 0000-0002-9113-5538
Observed ORCID: 0000-0002-9113-5538
OpenAlex ID: A5032577689
Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China
2016 · Xianping Lu, Zhiqiang Ning, et al. · Intractable & Rare Diseases Research · 177
PDF
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas
2012 · Mei Dong, Zhi-Qiang Ning, et al. · Cancer Chemotherapy and Pharmacology · 125
Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)
2021 · Linong Ji, Weihong Song, et al. · 中国科学通报：英文版 · 71
PDF
Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)
2021 · Weiping Jia, Jianhua Ma, et al. · 中国科学通报：英文版 · 51
PDF
Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study
2025 · Yameng Sun, Cuisong Wu, et al. · Hepatology · 20
Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas
2009 · M. Dong, Z. Ning, et al. · Journal of Clinical Oncology · 15
Impact of chiglitazar on glycemic control in type 2 diabetic patients with metabolic syndrome and insulin resistance: A pooled data analysis from two phase III trials
2023 · Zhiqiang Ning, Guoqiang Ai, et al. · Journal of Diabetes · 10
Discovery and Development of HDAC Subtype Selective Inhibitor Chidamide: Potential Immunomodulatory Activity Against Cancers
2016 · Xian‐Ping Lu, Zhi‐Qiang Ning, et al. · Wiley eBooks · 9
Efficacy and safety of chiglitazar add‐on to metformin in type 2 diabetes mellitus ( RECAM study)
2025 · Leili Gao, Linong Ji, et al. · Diabetes Obesity and Metabolism · 4
List of contributors
2025 · Tanvir Ahmed, Ahmed A. Al-Karmalawy, et al. · Elsevier eBooks
Chiglitazar/Carfloglitazar, a drug for the treatment of type 2 diabetes mellitus and more
2025 · Chenzhong Liao, Desi Pan, et al. · Elsevier eBooks
Pharmacokinetics and Safety of Chiglitazar in Patients with Renal Impairment: A Multicenter, Open-label, Parallel-controlled Phase I Clinical Trial
2025 · Jinjie Yuan, Jia Yu, et al. · Journal of Clinical and Nursing Research
PDF
Efficacy and Safety of the Peroxisome Proliferator-Activated Receptor Pan-Agonist Chiglitazar in Patients with Type 2 Diabetes (CMAP): A 24 Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial
2019 · Linong Ji, Weihong Song, et al. · SSRN Electronic Journal
Works count: 13
Citation count: 482
H-index: 8
I10-index: 7
Year
Topic
Type